The AVENIO Tumor Tissue CGP Kit V2 (Research Use Only. Not for use in diagnostic procedures.) was optimized to include fast workflows, higher throughput, and robust bioinformatics algorithms. Homologous Recombination Deficiency (HRDsig) Positive Percent Agreement (PPA) was assessed, as well as Microsatellite Instability (MSI), Tumor Mutation Burden (TMB), genomic Loss of Heterozygosity (gLOH), and 4 alteration classes (SNVs, Indels, Rearrangements, and Copy Number Alterations (CNA)). High agreement to FoundationOne® CDx (F1CDx®) was achieved, demonstrating high performance of an easy to use CGP assay.
This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.
Not a healthcare professional? Browse:
This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.